Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

F. Passiglia, C. Caglevic, E. Giovannetti, J. A. Pinto, P. Manca, S. Taverna, A. Listì, I. Gil-Bazo, L. E. Raez, A. Russo, C. Rolfo

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors’ microenvironment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment.
Original languageEnglish
Pages (from-to)259-268
Number of pages10
JournalSeminars in Cancer Biology
Volume52
Issue numberPt 2
DOIs
Publication statusPublished - 2018

Cite this

Passiglia, F. ; Caglevic, C. ; Giovannetti, E. ; Pinto, J. A. ; Manca, P. ; Taverna, S. ; Listì, A. ; Gil-Bazo, I. ; Raez, L. E. ; Russo, A. ; Rolfo, C. / Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. In: Seminars in Cancer Biology. 2018 ; Vol. 52, No. Pt 2. pp. 259-268.
@article{7fe4ff142cce4041a2ab781ceb47e8d4,
title = "Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment",
abstract = "Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors’ microenvironment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment.",
author = "F. Passiglia and C. Caglevic and E. Giovannetti and Pinto, {J. A.} and P. Manca and S. Taverna and A. List{\`i} and I. Gil-Bazo and Raez, {L. E.} and A. Russo and C. Rolfo",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
doi = "10.1016/j.semcancer.2018.01.015",
language = "English",
volume = "52",
pages = "259--268",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",
number = "Pt 2",

}

Passiglia, F, Caglevic, C, Giovannetti, E, Pinto, JA, Manca, P, Taverna, S, Listì, A, Gil-Bazo, I, Raez, LE, Russo, A & Rolfo, C 2018, 'Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment' Seminars in Cancer Biology, vol. 52, no. Pt 2, pp. 259-268. https://doi.org/10.1016/j.semcancer.2018.01.015

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. / Passiglia, F.; Caglevic, C.; Giovannetti, E.; Pinto, J. A.; Manca, P.; Taverna, S.; Listì, A.; Gil-Bazo, I.; Raez, L. E.; Russo, A.; Rolfo, C.

In: Seminars in Cancer Biology, Vol. 52, No. Pt 2, 2018, p. 259-268.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

AU - Passiglia, F.

AU - Caglevic, C.

AU - Giovannetti, E.

AU - Pinto, J. A.

AU - Manca, P.

AU - Taverna, S.

AU - Listì, A.

AU - Gil-Bazo, I.

AU - Raez, L. E.

AU - Russo, A.

AU - Rolfo, C.

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018

Y1 - 2018

N2 - Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors’ microenvironment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment.

AB - Recent studies with immunomodulatory agents targeting both cytotoxic T-lymphocyte protein 4 (CTLA4) and programmed cell death 1 (PD1)/programmed cell death ligand 1 (PDL1) have shown to be very effective in several cancers revealing an unexpected great activity in patients with both primary and metastatic brain tumors. Combining anti-CTLA4 and anti-PD1 agents as upfront systemic therapy has revealed to further increase the clinical benefit observed with single agent, even at cost of higher toxicity. Since the brain is an immunological specialized area it's crucial to establish the specific composition of the brain tumors’ microenvironment in order to predict the potential activity of immunomodulatory agents. This review briefly summarizes the basis of the brain immunogenicity, providing the most updated clinical evidences in terms of immune-checkpoint inhibitors efficacy and toxicity in both primary and metastatic brain tumors with the final aim of defining potential biomarkers for immunomodulatory cancer treatment.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041359373&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29391205

U2 - 10.1016/j.semcancer.2018.01.015

DO - 10.1016/j.semcancer.2018.01.015

M3 - Review article

VL - 52

SP - 259

EP - 268

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

IS - Pt 2

ER -